

**Congress of the United States**  
**Washington, DC 20515**

September 25, 2019

Norman Sharpless, M.D.  
Acting Commissioner  
Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Springs, MD 20993

Dear Acting Commissioner Sharpless,

We write to express our concerns about the effectiveness of the current Risk Evaluation and Mitigation Strategy (REMS) for mifepristone in light of the recent approval of a generic version and growing calls from abortion providers and advocates to remove restrictions. The use of mifepristone as a method to kill unborn babies has increased despite its proven health risks to women, and we are concerned that having this drug more readily available will have deeply troubling results.

Mifepristone, first approved in the United States in 2000, was previously only marketed under the brand name Mifeprex. Mifepristone is the first part of a two-drug chemical abortion process. It blocks progesterone, a hormone that nurtures the developing child throughout the pregnancy. By blocking the progesterone, mifepristone causes the mother's body to stop nourishing her unborn child. A second medication, misoprostol, is consumed to force the uterus to contract and expel the unborn baby.<sup>1</sup> Taking mifepristone to induce a chemical abortion is not a simple process. It is a multi-day progression of bleeding, cramping, contracting that, according to the Mifeprex ® medication guide may take up to 30 days to complete.<sup>2</sup>

In addition to the tragedy of aborting the unborn child, mifepristone presents serious health risks to the mother. The FDA has put in place REMS for mifepristone. REMS are required by the FDA for medications with serious safety concerns.<sup>3</sup> The REMS for mifepristone require it to only be dispensed by a certified prescriber in a clinic, medical office or hospital, and requires women to be informed of the potential complications associated with taking the drug. Healthcare providers who wish to become a certified prescriber must follow all guidelines listed in the REMS including a comprehensive review of the prescribing information and must sign a Prescriber Agreement Form to certify their ability to assess the gestation period accurately. Prescribers must also be able to diagnose an ectopic pregnancy (pregnancy outside the womb) and provide surgical intervention if necessary.<sup>3</sup>

These REMS, which now include the new generic mifepristone, do not go far enough to protect patient health. According to one study, women who have chemical abortions experience roughly four times the rate of adverse events as women whose babies are surgically aborted.<sup>4</sup> Although complete data is not available, the FDA reports that, since mifepristone was first approved on September 28, 2000, twenty-four women have died and thousands of women have experienced adverse events.<sup>5</sup> These include hospitalization, blood loss requiring a transfusion, severe or fatal infection, or ruptured ectopic pregnancies.<sup>6</sup> Even though the REMS require a provider who dispenses mifepristone to test for ectopic pregnancy, the FDA reports that at least 97 women with ectopic pregnancies have been given mifepristone; at least two women died

---

<sup>1</sup> Medication Guide (7/19/05), U.S. Food and Drug Administration, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020687s015MedG.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020687s015MedG.pdf).

<sup>2</sup> Medication Guide (7/19/05), U.S. Food and Drug Administration, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020687s015MedG.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020687s015MedG.pdf).

<sup>3</sup> Risk Evaluation and Mitigation Strategies (8/8/19), U.S. Food & Drug Administration, <https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems>.

<sup>4</sup> Maarit Niinimäki, M.D., et al., "Immediate Complications after Medical Compared with Surgical Termination of Pregnancy," 114 *Obstetrics & Gynecology* (Oct. 2009): 795-804. This study uses abortion outcome data collected in Finland, where medical registries used to track the government-based health care provided.

<sup>5</sup> Mifeprex Label, Reference ID: 3909592 (3/16), U.S. Food and Drug Administration, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/020687s0201bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s0201bl.pdf).


<sup>6</sup> Mifeprex Label, Reference ID: 3909592 (3/16), U.S. Food and Drug Administration, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/020687s0201bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s0201bl.pdf).

from ruptured ectopic pregnancy.<sup>7</sup> According to one study, an incomplete abortion can happen at least up to 10 percent of the time during chemical abortions and the risk increases after the 9th week of pregnancy.<sup>8</sup>


We vigorously oppose calls by Planned Parenthood<sup>9</sup> and other pro-abortion advocates<sup>10</sup> to remove the REMS for mifepristone. Allowing the drug to be available without medical supervision will have dire consequences for women and children. On the contrary, we agree with the American Academy of Pro-Life Obstetricians and Gynecologist (AAPLOG) that the current REMS offer insufficient protection for patients. At the least, it should be limited to 49 days' gestation (instead of the current 70 day limit), it should be administered under the supervision of a physician (instead of the currently-mandated "health care provider" who may be unable to rule out ectopic pregnancy and provide adequate care), and it should require three office visits by the patient.<sup>11</sup> To better understand the extent of the threat mifepristone poses to patients, the FDA should also mandate collecting complete, accurate information on all adverse events related to the drug. Since 2016, prescribers are only required to report deaths associated with mifepristone. Please consider reestablishing all four of these components from the 2000 REMS for mifepristone.

In order to discuss this matter further, we request a meeting with you by October 1, 2019. We appreciate your attention to these requests and look forward to reviewing a timely response.

Sincerely,



Jim Banks  
Member of Congress



Robert E. Latta  
Member of Congress



Doug Lamborn  
Member of Congress



Mike Kelly  
Member of Congress



Vicky Hartzler  
Member of Congress



Jeff Fortenberry  
Member of Congress

<sup>7</sup> RCM # 2007-525, NDA 20-687, Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018, U.S. Food and Drug Administration, <https://www.fda.gov/media/112118/download>.

<sup>8</sup> P. Sanhueza Smith, et al., "Safety, Efficacy and Acceptability of Outpatient Mifepristone-Misoprostol Medical Abortion Through 70 Days Since Last Menstrual Period in Public Sector Facilities in Mexico City," *Reproductive Health Matters* 22 (2015): 75-82, accessed May 6, 2015, <https://www.ncbi.nlm.nih.gov/pubmed/25702071>


<sup>9</sup> Former FDA Chief, Planned Parenthood: Remove 'Abortion Pill' REMS (8/21/19), *Inside Health Policy*, <https://insidehealthpolicy.com/inside-drug-pricing-daily-news/former-fda-chief-planned-parenthood-remove-'abortion-pill'-rems>.

<sup>10</sup> Jane E. Henney, M.D., et al., "Time to Reevaluate U.S. Mifepristone Restrictions," 381;7 *The New England Journal of Medicine* (Aug. 2019): 597-598.

<sup>11</sup> Citizen Petition from American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians, March 29, 2019, <https://www.regulations.gov/document?D=FDA-2019-P-1534-0001>.



Ralph Abraham, M.D.  
Member of Congress



Ann Wagner  
Member of Congress




Greg Gianforte  
Member of Congress



Andy Harris, M.D.  
Member of Congress



K. Michael Conaway  
Member of Congress



Ron Wright  
Member of Congress



Steve Chabot  
Member of Congress




Jeff Duncan  
Member of Congress




Bill Flores  
Member of Congress



Gus M. Bilirakis  
Member of Congress



Rodney Davis  
Member of Congress



Ted S. Yoho, DVM  
Member of Congress



Austin Scott  
Member of Congress



Roger Marshall, M.D.  
Member of Congress





Glenn Grothman  
Member of Congress




Bob Gibbs  
Member of Congress



Ron Estes  
Member of Congress



Bradley Byrne  
Member of Congress




Tim Walberg  
Member of Congress



Paul A. Gosar D.D.S.  
Member of Congress



Doug LaMalfa  
Member of Congress




Jim Jordan  
Member of Congress




Jody Hice  
Member of Congress



Andy Biggs  
Member of Congress




Blaine Luetkemeyer  
Member of Congress



Bruce Westerman  
Member of Congress



Buddy Carter  
Member of Congress



Bill Posey  
Member of Congress




Mark Meadows  
Member of Congress



Pete Olson  
Member of Congress



Ralph Norman  
Member of Congress



Randy Weber  
Member of Congress



Rick W. Allen  
Member of Congress




Roger Williams  
Member of Congress



David Rouzer  
Member of Congress



Brian Babin, D.D.S.  
Member of Congress




Barry Loudermilk  
Member of Congress



John Ratcliffe  
Member of Congress



Debbie Lesko  
Member of Congress



Billy Long  
Member of Congress




Gary Palmer  
Member of Congress



John Rutherford  
Member of Congress



Steve Watkins  
Member of Congress



James R. Baird  
Member of Congress



---

Ted Budd  
Member of Congress



---

Rick Crawford  
Member of Congress



---

John Rose  
Member of Congress